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Background: The serum levels of matrix metalloproteinases (MMPs) increase during chronic heart failure and the serum levels of MMP-2 are 
related to a poor prognosis. However, the roles of MMPs in acute heart failure (AHF) remain unclear. Therefore, we investigated whether MMPs 
changed during acute phase in patients with AHF. In addition, we evaluated whether the changes of MMPs affected their prognosis. 
Methods: The serum levels of MMP-2 and MMP-9 were measured in blood samples from 84 patients with AHF before starting initial treatment 
(Day1), on 3 (Day3) and 7 (Day7) days after admission, and before discharge (Pre-discharge). This study evaluated the relationships between 
MMPs and heart failure events, including cardiac death, readmission to the hospital for heart failure, and uncontrollable heart failure, and between 
ΔMMPs, which was defined as a change in the levels of MMPs from Day 1 to Day 3, and any heart failure events. The cutoff values of MMPs and 
ΔMMPs were determined from receiver operating characteristic curves and event free curves were constructed using a Kaplan-Meier analysis. 
Results: The serum levels of MMP-2 rapidly decreased significantly on Day3 in comparison to Day1 (900.3±303.4 vs. 1220.4±330.5 ng/ml; 
p<0.0001). The serum levels of MMP-9 also decreased significantly (72.3±59.0 vs. 107.0±102.4 ng/ml; p<0.01) on Day 3 in comparison to Day 1. 
The ΔMMP-2 values were significantly (p<0.05) greater in the event-free (n=54), than in the event (n=30) group (-364.7±260.1 vs. -229.5±229.3 
ng/ml, respectively). Kaplan-Meier curves showed that the prognosis of heart failure was significantly better among patients with greater reduction 
above -315 ng/ml of ΔMMP-2 values (p<0.05). 
Conclusion: The serum levels of MMP-2 decreased with improvements in AHF. Rapid reduction in MMP-2 might inhibit cardiac remodeling. The 
extent of the decrease in MMP-2 during the initial treatment for AHF was thus found to have a predictive power regarding heart failure events.
